Amyris (AMRS) Receiving Somewhat Positive Media Coverage, Analysis Finds

Media coverage about Amyris (NASDAQ:AMRS) has been trending somewhat positive on Tuesday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amyris earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.9056537716995 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have impacted Accern’s analysis:

Amyris (AMRS) opened at $3.17 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.65 and a debt-to-equity ratio of -0.76. Amyris has a 1 year low of $1.86 and a 1 year high of $14.85.

A number of brokerages have issued reports on AMRS. Zacks Investment Research upgraded Amyris from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. HC Wainwright set a $15.00 price target on Amyris and gave the stock a “buy” rating in a research report on Friday, August 11th. Cowen and Company set a $4.00 price target on Amyris and gave the stock a “hold” rating in a research report on Thursday, August 17th. Finally, ValuEngine upgraded Amyris from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Amyris currently has a consensus rating of “Hold” and a consensus target price of $20.69.

ILLEGAL ACTIVITY WARNING: “Amyris (AMRS) Receiving Somewhat Positive Media Coverage, Analysis Finds” was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply